{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T08:05:48Z","timestamp":1720944348625},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","liver.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.cld.2015.06.009","type":"journal-article","created":{"date-parts":[[2015,7,26]],"date-time":"2015-07-26T17:17:17Z","timestamp":1437931037000},"page":"707-716","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Next-Generation Regimens"],"prefix":"10.1016","volume":"19","author":[{"given":"John","family":"Vizuete","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hope","family":"Hubbard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Lawitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2015.06.009_bib1","unstructured":"Poordad F, Sievert W, Mollison L, et\u00a0al. All-oral, fixed-dose combination therapy with daclatasvir\/asunaprevir\/beclabuvir for non-cirrhotic patients with chronic HCV genotype 1 infection: UNITY-1 phase 3 SVR-12 results [LB-7]. Presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, November 10, 2014."},{"key":"10.1016\/j.cld.2015.06.009_bib2","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"Ferenci","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2015.06.009_bib3","unstructured":"Muir AJ, Poordad F, Lalezari J, et\u00a0al. All-oral, fixed-dose combination therapy with daclatasvir\/asunaprevir\/beclabuvir \u00b1 ribavirin, for patients with chronic HCV genotype 1 infection and compensated cirrhosis: UNITY-2 phase 3 SVR12 results [LB-2]. Presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, November 10, 2014."},{"key":"10.1016\/j.cld.2015.06.009_bib4","doi-asserted-by":"crossref","unstructured":"Nelson DR, Cooper JN, Lalezari JP, et\u00a0al. All-oral 12-week combination treatment with daclatasvir (DCV) and sofosbuvir (SOF) in patients infected with HCV genotype (GT) 3: ALLY-3 phase 3 study [LB-2]. Presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, November 9, 2014.","DOI":"10.1016\/S0168-8278(15)30985-5"},{"key":"10.1016\/j.cld.2015.06.009_bib5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2015.06.009_bib6","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2015.06.009_bib7","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2015.06.009_bib8","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2015.06.009_bib9","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(14)61793-1","volume":"385","author":"Sulkowski","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2015.06.009_bib10","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(14)61795-5","volume":"385","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2015.06.009_bib11","unstructured":"Lawitz E, Poordad F, Gutierrez JA, et\u00a0al. C-SWIFT: grazoprevir (MK-5172)+ elbasvir (MK-8742)+ sofosbuvir in treatment-naive patients with hepatitis C virus genotype 1 infection, with and without cirrhosis, for durations of 4, 6, or 8 weeks (interim Results) [LB-33]. Presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, November 9, 2014."},{"key":"10.1016\/j.cld.2015.06.009_bib12","doi-asserted-by":"crossref","unstructured":"Everson GT, Tran TT, Towner WJ, et\u00a0al. Safety and efficacy of treatment with the interferon-free, ribavirin-free combination of sofosbuvir+ Gs-5816 for 12 weeks in treatment naive patients with genotype 1\u20136 HCV infection [abstract 111]. Presented at the 49th annual meeting of the European Association for the Study of the Liver. London, April 11, 2014.","DOI":"10.1016\/S0168-8278(14)60113-6"},{"key":"10.1016\/j.cld.2015.06.009_bib13","unstructured":"Tran TT, Morgan TR, Thuluvath PJ, et\u00a0al. Safety and Efficacy of treatment with sofosbuvir+ GS-5816+\/\u2212 ribavirin for 8 or 12 weeks in treatment naive patients with genotype 1-6 HCV infection [abstract: 80]. Presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, November 9, 2014."},{"key":"10.1016\/j.cld.2015.06.009_bib14","doi-asserted-by":"crossref","unstructured":"Muir A, Hill J, Lawitz E, et\u00a0al. ACH-3102, a second generation NS5A inhibitor, demonstrates potent antiviral activity in patients with genotype 1a HCV infection despite the presence of baseline NS5A-resistant variants [abstract 398]. Presented at the 48th annual meeting of the European Association for the Study of the Liver. Amsterdam, April 27, 2013.","DOI":"10.1016\/S0168-8278(13)60878-8"},{"key":"10.1016\/j.cld.2015.06.009_bib15","unstructured":"Gane EJ, Kocinsky H, Schwabe C, et\u00a0al. Interim sustained virologic response (SVR), safety and tolerability results of 8-week treatment with ACH-3102 and sofosbuvir in chronic hepatitis C (HCV), genotype-1 (GT-1), treatment-naive patients: a phase 2 \u201cproxy\u201d study [LB-32]. Presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, November 9, 2014."},{"key":"10.1016\/j.cld.2015.06.009_bib16","unstructured":"Achillion achieves 100% SVR12 in phase 2 trial evaluating 6-week combination treatment with ACH-3102. 2015. Available at: http:\/\/ir.achillion.com\/releasedetail.cfm?releaseid=895306. Accessed February 11, 2015."},{"key":"10.1016\/j.cld.2015.06.009_bib17","unstructured":"Lawitz E, O'Riordan WD, Freilich BL, et\u00a0al. Potent antiviral activity of ABT-493 and ABT-530 with 3-day monotherapy in patients with and without compensated cirrhosis with hepatitis C virus (HCV) genotype 1 infection [abstract 1956]. Presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, November 9, 2014."},{"key":"10.1016\/j.cld.2015.06.009_bib18","unstructured":"Gane EJ, Sicard E, Popa S, et\u00a0al. A phase I\/IIa study assessing 7-day dosing of MK-3682 (formerly IDX21437) in subjects infected with hepatitis C virus (HCV) [abstract: 1974]. Presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, November 9, 2014."},{"key":"10.1016\/j.cld.2015.06.009_bib19","unstructured":"Asante-Appiah E, Liu R, Curry S, et\u00a0al. MK-8408, A potent and selective NS5A inhibitor with a high genetic barrier to resistance and activity against HCV genotypes 1\u20136 [abstract: 1979]. Presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, November 9, 2014."},{"key":"10.1016\/j.cld.2015.06.009_bib20","unstructured":"Lahser F, Bystol K, Curry S, et\u00a0al. The combination of MK-5172, an NS3 inhibitor, and MK-8408, an NS5A inhibitor, presents a high genetic barrier to resistance in HCV genotypes [abstract: 1988]. Presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, November 9, 2014."},{"key":"10.1016\/j.cld.2015.06.009_bib21","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1126\/science.1113329","article-title":"Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA","volume":"309","author":"Jopling","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.cld.2015.06.009_bib22","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrd4359","article-title":"Therapeutic targeting of microRNAs: current status and future challenges","volume":"13","author":"Li","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cld.2015.06.009_bib23","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1038\/ncomms6408","article-title":"Hepatitis C virus genetics affects miR-122 requirements and response to miR-122 inhibitors","volume":"18","author":"Israelow","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.cld.2015.06.009_bib24","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV infection by targeting microRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2015.06.009_bib25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.antiviral.2014.08.015","article-title":"Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients","volume":"111","author":"Van der Ree","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.cld.2015.06.009_bib26","unstructured":"All HCV patients treated with a single SC administration of 4 mg\/kg of RG-101 responded with mean viral load reduction of 4.8 log10 at Day 29 and 9\/14 patients are below the limit of quantification at Day 57. 2015. Available at: http:\/\/ir.regulusrx.com\/releasedetail.cfm?ReleaseID-=895314. Accessed February 11, 2015."}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326115000641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326115000641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T19:03:17Z","timestamp":1567018997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326115000641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S1089326115000641"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2015.06.009","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-Generation Regimens","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2015.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}